Faina Shtern, MD, presented “A Review of the Third Global Summit on Precision Diagnosis and Treatment of Prostate Cancer” during the 29th Annual International Prostate Cancer Update on January 26, 2019 in Beaver Creek, Colorado.

How to cite: Shtern, Faina  “A Review of the Third Global Summit on Precision Diagnosis and Treatment of Prostate Cancer” January 26, 2019. Accessed Nov 2024. https://dev.grandroundsinurology.com/androgen-annihilation-as-a-new-therapeutic-paradigm-in-advanced-prostate-cancer/

A Review of the Third Global Summit on Precision Diagnosis and Treatment of Prostate Cancer – Summary

Faina Shtern, MD, reviews the history of AdMeTech Foundation, highlighting efforts such as their Manogram® project and “Brain Trust” program. She then summarizes the findings and recommendations from the foundation’s Third Global Summit on Precision Diagnosis and Treatment of Prostate Cancer.

Abstract:

The 3rd Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer (PC) took place on August 3-5, 2018 in Boston. This event brought together key opinion leaders and highlighted the following emerging trends in precision care and related research:

    1. Radiogenomics – integrating quantitative imaging (radiomics) and genomics – can make a significant impact on precision care.
    2. Rapidly expanding discovery of new genetic and molecular targets are critical for further development and integration of in vitro diagnostics, molecular imaging, and individualized care.
    3. Precision diagnosis has had an impact on the selection of patients for appropriate treatment and follow-up.
    4. Validated liquid biomarkers and their integration with imaging (e.g., MRI) may improve patient selection for biopsy.
    5. Fusion of Transrectal Ultrasound with MRI is important for improved biopsy tissue sampling for routine pathologic assessment and genetic tissue profiling. High-resolution micro-ultrasound may improve clinical value of MRI/US Fusion Guidance.
    6. Multiple promising in vitro novel liquid and tissue biomarkers and in vivo imaging tools have emerged recently for improved assessment of early and advanced PC and require further research.
    7. Further expert consensus and research is needed to define clinical indications for adding genetic cancer profiling to standard pathologic examination of biopsy samples and routine pathologic examination of post-surgical specimens.
    8. Machine Learning is likely to be required for multi-factorial, multi-modality data analysis.
    9. Several areas of imaging, including:
      1. mpMRI, which, while remaining the most broadly used imaging tool before and after diagnosis, requires further standardization of image acquisition, quality, and interpretation; and –
      2. Molecular and multi-modality imaging, which may improve clinical assessment of advanced PC, early diagnosis of recurrence, and biologic characterization of the early stages of localized disease.
    10. Image-Guided Focal Treatment emerged as a promising, credible additional option to Active Surveillance and Immediate Whole-Gland Treatment.

About the International Prostate Cancer Update

The International Prostate Cancer Update (IPCU) is an annual, multi-day CME conference focused on prostate cancer treatment updates. The conference’s faculty consists of international experts, and the event caters to urologists, medical oncologists, radiation oncologists, and other healthcare professionals. Topics encompass prostate cancer management, from diagnosis to treating advanced and metastatic disease. Dr. Shtern presented this lecture during the 29th IPCU in 2019. Please visit this page in order to learn more about future IPCU meetings.

ABOUT THE AUTHOR

Faina Shtern, MD

Faina Shtern, MD, is the President and CEO of AdMeTech Foundation, a non-profit dedicated to ending the prostate cancer crisis. As a Founder of AdMeTech, Faina Shtern, MD, has been leading groundbreaking programs in prostate cancer research, education, awareness and advocacy, with a focus on the advancement of precision diagnostics and their integration with precision treatment, since 1997. This work has led to:

a) Development, global PI-RADS standardization, clinical evaluation, and implementation of precision MRI;
b) Establishment of molecular imaging, with priority focus on PSMA PET;
c) Original work in robotics for precision biopsy and treatment;
d) Recognition and expansion of radiogenomics; and
e) Precedent-setting legislation in US Congress and Massachusetts.

Prior to founding AdMeTech, Dr. Shtern served as Chief of the Diagnostic Imaging Research Branch at the National Cancer Institute, and Associate Director for Science and Technology, Office of Women’s Health, Office of the Secretary, US Department of Health and Human Services. She also led radiology research at Harvard Medical School’s Beth Israel Deaconess Medical Center and at Boston Children’s Hospital between 1999 and 2008.

Dr. Shtern has led and participated in numerous scientific and advisory committees, including the Breast Cancer Study Group of the National Academy of Medicine and Vice President Biden’s Cancer Moonshot Program. In 2016, she was named a “Woman of Influence” by the Boston Business Journal.